Diagnos Financials

ADK Stock  CAD 0.28  0.01  3.70%   
We urge to utilize Diagnos fundamental analysis to find out if markets are presently mispricing the company. Put another way you can exercise it to find out if Diagnos is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We were able to interpolate thirty-one available fundamental indicators for Diagnos, which can be compared to its peers. The stock experiences an unexpected upward trend. Watch out for market signals. Check odds of Diagnos to be traded at C$0.336 in 90 days. Key indicators impacting Diagnos' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio0.240.2509
Sufficiently Down
Slightly volatile
  
Understanding current and past Diagnos Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Diagnos' financial statements are interrelated, with each one affecting the others. For example, an increase in Diagnos' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Diagnos' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Diagnos. Check Diagnos' Beneish M Score to see the likelihood of Diagnos' management manipulating its earnings.

Diagnos Stock Summary

Diagnos competes with VentriPoint Diagnostics, and Theralase Technologies. DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally. The company was founded in 1998 and is headquartered in Brossard, Canada. DIAGNOS INC operates under Health Information Services classification in Canada and is traded on TSX Venture Exchange.
Foreign Associate
  USA
Specialization
Health Care, Health Care Equipment & Services
InstrumentCanada Stock View All
ExchangeTSX Venture Exchange
ISINCA2524423068
Business Address7005 Taschereau Boulevard,
SectorHealth Care Technology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.diagnos.ca
Phone450 678 8882
CurrencyCAD - Canadian Dollar
You should never invest in Diagnos without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Diagnos Stock, because this is throwing your money away. Analyzing the key information contained in Diagnos' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Diagnos Key Financial Ratios

There are many critical financial ratios that Diagnos' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Diagnos reports annually and quarterly.

Diagnos Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets2.4M2.0M1.5M823.0K663.8K630.6K
Net Debt(232.9K)112.3K764.9K1.8M3.0M3.1M
Retained Earnings(40.3M)(42.4M)(45.0M)(47.5M)(50.6M)(48.1M)
Accounts Payable67.8K190.1K278.5K288.2K330.4K214.2K
Cash570.4K359.4K420.9K296.6K219.0K381.1K
Net Receivables321.4K175.7K324.2K50.2K166.6K158.2K
Total Liab614.8K818.2K1.7M2.8M3.7M1.9M
Total Current Assets2.3M1.6M1.3M574.8K406.9K386.5K
Other Current Liab205.2K152.3K184.2K6.7K191.3K162.6K
Short Term Debt303.8K203.6K190.1K1.1M1.3M897.8K
Common Stock33.7M34.8M35.7M35.9M37.7M26.7M
Inventory(21.7K)118.5K32.8K28.8K33.1K43.6K
Other Current Assets26.1K21.7K14.9K20.5K21.3K27.6K
Net Tangible Assets(5.1M)1.8M1.1M(113.5K)(130.5K)(137.1K)
Short Long Term Debt1.7M268.5K125K168.9K975.9K971.4K
Net Invested Capital2.1M1.3M843.1K120.4K(130.2K)(123.7K)
Net Working Capital1.8M1.0M629.4K(144.0K)(1.2M)(1.2M)
Capital Stock33.7M34.8M35.7M35.9M37.7M36.9M

Diagnos Key Income Statement Accounts

201920202021202220232024 (projected)
Total Revenue331.5K267.1K438.8K485.7K170.2K161.7K
Gross Profit(473.5K)(347.5K)(418.3K)(306.8K)(837.9K)(796.0K)
Operating Income(2.7M)(2.0M)(2.6M)(2.2M)(2.6M)(2.7M)
Ebit(2.7M)(2.0M)(2.5M)(2.6M)(2.3M)(2.5M)
Ebitda(2.6M)(1.9M)(2.4M)(2.1M)(2.5M)(2.6M)
Income Before Tax(3.4M)(2.1M)(2.6M)(2.5M)(3.1M)(3.3M)
Net Income(3.4M)(2.1M)(2.6M)(2.5M)(3.1M)(3.3M)
Income Tax Expense432.9K296.4K153.9K1.01.151.09
Interest Expense347.1K32.2K53.8K278.9K550.2K454.5K
Cost Of Revenue805.0K614.6K857.1K792.5K1.0M1.0M
Net Interest Income(343.9K)(32.2K)(48.4K)(271.1K)(543.3K)(570.4K)

Diagnos Key Cash Accounts

201920202021202220232024 (projected)
Change In Cash432.2K(211.1K)61.5K(124.3K)(77.6K)(73.7K)
Free Cash Flow(2.7M)(1.4M)(2.1M)(1.9M)(2.4M)(2.5M)
Depreciation101.7K87.4K105.8K101.2K124.2K122.0K
Other Non Cash Items381.1K32.4K30.5K123.0K522.9K351.0K
Capital Expenditures15.1K42.2K31.0K24.2K10.9K10.3K
Net Income(3.4M)(2.1M)(2.6M)(2.5M)(3.1M)(3.3M)
End Period Cash Flow570.4K359.4K420.9K296.6K219.0K381.1K
Investments(764.5K)300K530K500K(14.0K)(13.3K)
Net Borrowings467.8K(206.8K)894.9K1.4M1.3M743.7K
Change To Netincome660.7K296.5K479.5K394.2K453.4K630.4K

Diagnos Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Diagnos's current stock value. Our valuation model uses many indicators to compare Diagnos value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Diagnos competition to find correlations between indicators driving Diagnos's intrinsic value. More Info.
Diagnos is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . At this time, Diagnos' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Diagnos' earnings, one of the primary drivers of an investment's value.

Diagnos Systematic Risk

Diagnos' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Diagnos volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Diagnos correlated with the market. If Beta is less than 0 Diagnos generally moves in the opposite direction as compared to the market. If Diagnos Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Diagnos is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Diagnos is generally in the same direction as the market. If Beta > 1 Diagnos moves generally in the same direction as, but more than the movement of the benchmark.

Diagnos Total Assets Over Time

Today, most investors in Diagnos Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Diagnos' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Diagnos growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.42)

At this time, Diagnos' Price Earnings To Growth Ratio is fairly stable compared to the past year.

Diagnos November 28, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Diagnos help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Diagnos. We use our internally-developed statistical techniques to arrive at the intrinsic value of Diagnos based on widely used predictive technical indicators. In general, we focus on analyzing Diagnos Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Diagnos's daily price indicators and compare them against related drivers.

Additional Tools for Diagnos Stock Analysis

When running Diagnos' price analysis, check to measure Diagnos' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Diagnos is operating at the current time. Most of Diagnos' value examination focuses on studying past and present price action to predict the probability of Diagnos' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Diagnos' price. Additionally, you may evaluate how the addition of Diagnos to your portfolios can decrease your overall portfolio volatility.